Blog

- June 30, 2026

Saluda Medical Receives U.S. FDA Approval for New CAP24™ Surgical Paddle Lead

BLOOMINGTON, Minn., June 30, 2026 /PRNewswire/ — Saluda Medical, Inc. (ASX: SLD, “Saluda” or the “Company”), a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel closed-loop neuromodulation platform, today announced that the U.S. Food and Drug Administration (“FDA”) has approved Saluda’s CAP24 paddle lead, allowing it to be marketed and sold in the U.S.

Read More »